Nancy Holekamp
Ophthalmology · Chesterfield, MONPI 1831197557
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.9%. Reporting peaked in 2019 at $269,217 and has fallen 99.9% since, to $300 in 2025. Among ophthalmology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 496 payments — averaging $1548.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$183K
- AbbVie$133K
- Genentech USA, Inc.$99K
- F. Hoffmann-la Roche AG$89K
- Genentech, Inc.$76K
- Novartis$54K
- plus $134K from 22 others
Across 296 payments — averaging $6785.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.9M
- F. Hoffmann-la Roche AG$92K
- Regeneron$10K
- AbbVie$10K
- Alimera Sciences, Inc.$4K
What the payments were for
- Consulting fees$424,83155%
- Speaking & faculty fees$291,98838%
- Travel & lodging$40,1965%
- Food & beverage$10,0871%
- Education$9190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 88 | $183,236 |
| AbbVie(2 entities) | 117 | $133,427 |
| Genentech USA, Inc. | 74 | $98,996 |
| F. Hoffmann-la Roche AG | 26 | $88,693 |
| Genentech, Inc. | 27 | $76,265 |
| Novartis | 30 | $53,760 |
| Apellis Pharmaceuticals, Inc. | 17 | $31,281 |
| Regeneron | 15 | $23,907 |
| Spark Therapeutics, Inc. | 11 | $17,323 |
| Roche Products Limited | 6 | $14,852 |
| Bausch & Lomb Americas Inc. | 20 | $14,487 |
| Biogen | 4 | $10,644 |
| Eyepoint US, Inc. | 11 | $6,961 |
| Boehringer Ingelheim International GmbH | 6 | $4,800 |
| Cardinal Health 108 LLC | 2 | $4,050 |
| Alimera Sciences, Inc. | 13 | $3,405 |
| Novartis Pharma AG | 1 | $1,050 |
| Notal Vision, Inc. | 1 | $300 |
| Mallinckrodt Hospital Products Inc. | 3 | $189 |
| Sun Pharmaceutical Industries Inc. | 8 | $167 |
| Kala Pharmaceuticals, Inc. | 3 | $56 |
| Alcon | 2 | $34 |
| Sight Sciences, Inc. | 1 | $34 |
| Oyster Point Pharma, Inc. | 2 | $31 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $29 |
| Biotissue Holdings Inc. | 4 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$206,416
- VABYSMO$77,691
- OZURDEX$67,266
- Lucentis$61,582
- BEOVU$50,919
- SUSVIMO$40,533
- Non-Covered Product$30,877
- LUXTURNA$17,160
- XIPERE$12,383
- YUTIQ$6,795
- Iluvien$3,200
- RTH258A_BEOVU_OPHTHALMOLOGY$1,050
- Foresee Home$300
- ACTHAR$123
How this compares
$768,021 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Chesterfield
- Jay PeposeChesterfield$516K
- Paul TesserChesterfield$29K
- Mujtaba QaziChesterfield$15K
- Ibrahim Sayed-AhmedChesterfield$9K
- Steven SilversteinKansas City$872K
- Ranjan MalhotraSaint Louis$809K
- Gregg BerdySaint Louis$360K
- Joseph GiraDes Peres$174K
- Joseph TauberKansas City$174K
- Jella AnColumbia$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.